826 abstracts found.



Results filter

Discovery of New Pathways and Mechanisms of Notch Signalling in Angiogenesis

Year:

Session type:

Esther Bridges1,Anassuya Ramachandran1,Jie Zuo1,Tessa Peterkin1,Martin Taylor2,Harukazu Suzuki3,Philip Pinheiro1,Ji-Liang Li1,Roger Patient1,Adrian Harris1
1Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom,2Human Genetics Unit, University of Edinburgh, Edinburgh, United Kingdom,3RIKEN Omics Science Center, Yokohama Institute, Yokohama, Japan

Targeting Notch in Pancreatic Cancer

Year:

Session type:

Natalie Cook1,Kris Frese1,Mike Jacobetz1,Meredith Caldwell-Jacobetz1,Tashinga Bapiro1,Aimee Michael2,Christopher Winter2,Duncan Jodrell1,David Tuveson1
1Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom,2Merck Research Laboratories, Boston, United States

Fbw7 regulates intestinal cell lineage commitment and is a haploinsufficient suppressor of intestinal tumourigenesis

Year:

Session type:

Rocio Sancho1,Anett Jandke1,Hayley Davis2,Markus Diefenbacher1,Ian Tomlinson2,Axel Behrens1
1Cancer Research UK - London Research Institute, London, United Kingdom,2University of Oxford, Oxford, United Kingdom

FUS/TLS is a novel mediator of androgen-dependent cell cycle progression and prostate cancer growth.

Year:

Session type:

Greg Brooke1,Rachel Culley1,Alwyn Dart1,Bradley Spencer-Dene1,Marjorie Walker1,Charlotte Bevan1
1Imperial College London, London, United Kingdom

Regulators of mitotic transition determine paclitaxel resistance in vitro and predict poor prognosis in breast cancer in vivo

Year:

Session type:

Rebecca A. Burrell1,Sarah McClelland1,Nicolai Juul2,Zoltan Szallasi2,Charles Swanton1
1Translational Cancer Therapeutics, CRUK London Research Institute, London WC2A 3PX, United Kingdom,2Center for Biological Sequence Analysis, Technical University of Denmark, DK-2800 Lyngby, Denmark

An inducible caspase-3 ‘tumour death switch’ model to identify and quantify circulating biomarkers of apoptotic cell death using iTRAQ isobaric tags and mass spectrometry

Year:

Session type:

Kathryn Simpson1,Cassandra Hodgkinson1,Michael Walker1,Martin Dawson1,Lee Lancashire1,Cong Zhou1,Marion MacFarlane2,Anthony Whetton3,Caroline Dive1
1Paterson Institute for Cancer Research, Manchester Academic Health Science Centre, Christie Hospital, University of Manchester, Manchester, United Kingdom,2MRC Toxicology Unit, University of Leicester, Leicester, United Kingdom,3School of Cancer and Enabling Sciences, Manchester Academic Health Science Centre, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, United Kingdom

ACP McElwain Prize: P-Rex1 is a central component of metastasis in malignant melanoma

Year:

Session type:

Colin Lindsay1,Samuel Lawn1,William Faller1,Andrew Campbell1,Channing Der2,Kate Pedone2,Heidi Welch3,Lionel LaRue4,Iain Jackson5,Friedrich Beerman6,Brad Ozanne1,Owen Sansom1
1The Beatson Institute for Cancer Research, Glasgow, UK,2The University of North Carolina, Chapel Hill, USA,3The Babraham Institute, Cambridge, UK,4Centre de Recherche, Institut Curie, Paris, France,55MRC Human Genetics Unit, Edinburgh, UK,6ISREC, Epalinges, Switzerland

BACR AstraZeneca Young Scientist Frank Rose Award: HNRNPUL-1 promotes DNA double-strand break end resection

Year:

Session type:

Grant Stewart1
1University of Birmingham, UK

Identification of a SNP  in the KLK3 gene which predisposes to prostate cancer – the first coding SNP to be discovered in this disease

Year:

Session type:

Zsofia Kote-Jarai1,Ali Amin Al Olama2,Daniel Leongamornlert1,Malgorzata Tymrakiewicz1,Edward Saunders1,Nathan Brown1,Michelle Guy1,Graham Giles3,Gianluca Severi3,John Hopper3,Melissa Southey3,Freddy Hamdy4,David Neal2,Jenny Donovan5,Kenneth Muir6,Douglas Easton2,Rosalind Eeles1
1The Institute of Cancer Research, Sutton, United Kingdom,2The University of Cambridge, Cambridge, United Kingdom,3University of Melbourne, Melbourne, Australia,4University of Oxfrod, Oxford, United Kingdom,5University of Bristol, Bristol, United Kingdom,6University of Warrick, Warrick, United Kingdom

Genotypic profiling of 452 choroidal melanomas with Multiplex Ligation-Dependent Probe Amplification (MLPA) suggests crescendo malignancy

Year:

Session type:

Bertil Damato1,Justyna Dopierala1,Sarah Coupland1
1School of Cancer Studies, University of Liverpool, Liverpool, United Kingdom

Gene-environment interactions and breast cancer: prospective evidence from 7610 women with breast cancer in a large UK cohort

Year:

Session type:

Ruth Travis1,Gillian Reeves1,Valerie Beral1
1Cancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom

CARMA3 shRNA induces cisplatin sensitivity in ovarian cancer cells

Year:

Session type:

Jiyuan Sun1,Ganesh Panta2
1The University of Texas MD Anderson Cancer Center, Houston, Texas, United States,2IDEXX Labs, Westbrook, Maine, United States

??‘Why it’s not for us’: the views of parents and girls in the UK who declined the HPV vaccination – a qualitative study

Year:

Session type:

Alison Clements1,Lorna Henderson1,Joan Austoker1
1University of Oxford, Oxford, United Kingdom

The Prognostic Significance of Androgen Receptor Phosphorylation in Prostate Cancer

Year:

Session type:

Si Jie Heng1,Claire Tannahill1,Claire Adams1,Pamela McCall1,Morag Seywright2,Mark Underwood3,Joanne Edwards1
1University of Glasgow, Glasgow, United Kingdom,2Western Infirmary, Glasgow, United Kingdom,3Glasgow Royal Infirmary, Glasgow, United Kingdom

A validation study of genes and polymorphisms associated with radiation toxicity: preliminary results of the RAPPER study

Year:

Session type:

Gillian Barnett1,Catharine West3,Caroline Baynes1,Craig Luccarini1,Don Conroy1,Charlotte Coles2,Rebecca Elliott1,Neil Burnet2,Paul Pharoah1,Alison Dunning1
1Strangeways Research Laboratory, Cambridge, United Kingdom,2Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom,3University of Manchester, Christie Hospital, Manchester, United Kingdom

Targeting c20orf20 for cutaneous squamous cell carcinoma therapy

Year:

Session type:

Stephen Watt1,Celine Pourreyron1,John Foerster1,Karin Purdie2,Clare Cole1,John McGrath1,Charlotte Proby1,Irene Leigh1,Andrew South1
1University of Dundee, Dundee, United Kingdom,2University of London, London, United Kingdom

Early results of the RCGP/NCAT National Audit of Cancer Diagnosis in Primary Care

Year:

Session type:

Sean McPhail1,Kathy Elliott2,Greg Rubin3
1NCIN, London, United Kingdom,2NCAT, London, United Kingdom,3University of Durham, Durham, United Kingdom

Defining and measuring key timepoints and intervals in early diagnosis research: outcomes of a consensus working group

Year:

Session type:

David Weller1,Christine Campbell1,Richard Neale2,Sadia Nafees2
1University of Edinburgh, Scotland, United Kingdom,2North Wales Clinical School, Wrexham, United Kingdom

Hormone replacement therapy, oral bisphosphonates and risk of gastrointestinal cancer

Year:

Session type:

Jane Green1,Gabriela Czanner1,Gillian Reeves1,Joanna Watson1,Lesley Wise2,Valerie Beral1
1University of Oxford, Oxford, United Kingdom,2Medicines and Healthcare products Regulatory Agency, London, United Kingdom

Insulin-like growth factors (IGFs) and IGF binding proteins in PSA-detected prostate cancer: a large population-based case-control study

Year:

Session type:

Mari-Anne Rowlands1,Jeff MP Holly1,David Gunnell1,Jenny Donovan1,J Athene Lane1,Freddie Hamdy2,David E Neal3,Richard M Martin4
1University of Bristol, Bristol, United Kingdom,2University of Oxford, Oxford, United Kingdom,3University of Cambridge, Cambridge, United Kingdom,4MRC Centre for Causal Analysis in Translational Epidemiology, Bristol, United Kingdom

MYC-dependent regulation and prognostic role of MYC stabilizing protein, CIP2A, in  human gastric cancer

Year:

Session type:

Anchit Khanna1,Camilla Böckelman2,Annabrita Hemmes2,Melissa R Junttila3,Jan-Patrik Wiksten2,Mikael Lundin2,Siina Junnila2,Daniel J. Murphy3,Gerard I. Evan3,Caj Haglund2,Jukka Westermarck1,Ari Ristimäki2
1Institute of Medical Technology,University of Tampere and Tampere University Hospital,, Tampere, Finland,2University of Helsinki, Helsinki, Finland,3University of California, San Francisco, United States

Polycomb-mediated regulation of the INK4/ARF tumour suppressor locus

Year:

Session type:

Emma Anderton1,Marc Rodriguez-Niedenfuhr1,Goedele Maertens1,Selma El Messaoudi-Aubert1,Tomas Racek1,Julie Stock1,Gordon Peters1
1Cancer Research UK London Research Institute, London, United Kingdom

Results of ICON7: a phase III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Medical Research Council Cancer Trials Unit, presented on behalf of the GCIG ICON7 collaborators

Year:

Session type:

Jonathan Ledermann2, Charlie Gourley3, Sharadah Essapen4, Gordon Rustin5, Fiona Collinson1, Sheryl Sim1, Faisal Al-Terkait1, Clare Griffin6
2UCL Cancer Institute and Cancer Research UK and UCL Cancer Trials Centre, London, UK,3University of Edinburgh Cancer Research Centre and Western General Hospital, UK,4Royal Surrey County Hospital, Guildford, UK,5Mount Vernon Hospital, Northwood, UK,6Medical Research Council Cancer Trials Unit, London, UK

Results of BC2001: A 2×2 phase III randomised trial of synchronous chemo-radiotherapy (CRT) compared to radiotherapy (RT) alone and standard (sRT) versus reduced high-dose volume RT (rvRT) in muscle invasive bladder cancer (MIBC) (CRUK/01/004

Year:

Session type:

Syed Hussain1, Emma Hall2, Peter Jenkins3, Jean Tremlett4, Christine Rawlings5, Malcolm Crundwell6, Rebecca Lewis2, Carey Hendron1, Rachel Waters2, Robert Huddart2
2The Institute of Cancer Research, Sutton, UK,3Cheltenham General Hospital, UK,4Brighton and Sussex University Hospitals NHS Trust, UK,5South Devon Healthcare NHS Foundation Trust, Torbay, UK,6Royal Devon and Exeter Hospital, UK

The MRC Myeloma IX Trial: beneficial effects of thalidomide and zoledronic acid for newly diagnosed myeloma patients of all ages

Year:

Session type:

Walter Gregory1, Faith Davies2, Kim Cocks1, Sue Bell1, Alex Szubert1, Nuria NavarroCoy1, Mark Drayson3, Roger Owen4, Gordon Coo4, Fiona Ross5, Graham Jackson6, Sylvia Feyler7, John Ashcroft8, Gareth Morgan2
2The Institute of Cancer Research, Royal Marsden Hospital, London, UK,3University of Birmingham, UK,4St James’s University Hospital, Leeds, UK,5University of Southampton, UK,6University of Newcastle, UK,7Calderdale and Huddersfield NHS Trust, Huddersfield, UK,8Mid Yorkshire Hospitals NHS Trust, Wakefield, UK

Intergroup randomized controlled phase III trial of Androgen Deprivation Therapy (ADT) +/- Radiation Therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC, INT: T94-0110; NCT00002633)

Year:

Session type:

Padraig R Warde2, Matthew R Sydes3, Keyue Ding8, Mary K Gospodarowicz2, Gregory P Swanson4, Peter Kirkbride5, Ed Kostashuk6, John Hetherington7, Andrea Hiltz8, Karen Sanders3, John Anderson5, Jim Barber1, Mahesh KB Parmar3, Wendy Parulekar8
2Princess Margaret Hospital and University of Toronto, Canada,3MRC Clinical Trials Unit, London, UK,4University of Texas Health Science Center, San Antonio, USA,5Weston Park Hospital, Sheffield, UK,6British Columbia Cancer Agency, Surrey, Canada,7Castle Hill Hospital, Hull, UK,8NCIC Clinical Trials Group, Kingston, Canada